[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639878":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-6222","EXPERIMENTAL","Participants will be administered a single dose of ALN-6222.",[13],"Drug: ALN-6222",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-6222 will be administered subcutaneously (SC).",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered SC.",[15],[30],{"name":31,"affiliation":5,"role":32},"Medical Director","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":35,"role":36,"phone":40,"phoneExt":25,"email":38},"1-877-256-9526",[42],{"facility":43,"status":44,"city":45,"state":25,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":25},"Clinical Trial Site","RECRUITING","Mount Royal","H3P 3P1","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-73.64918,45.51675,{"lat":53,"lon":52},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100639878","phase-1-a-study-to-evaluate-aln-6222-in-participants-with-obesity-100639878",false,"NCT07624071","A Study to Evaluate ALN-6222 in Participants With Obesity","A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity","Inclusion Criteria -\n\n* Is an adult patient with a body mass index ≥30 kg\u002Fm\\^2 to \\\u003C40 kg\u002Fm\\^2\n* Has a hemoglobin A1c \\\u003C6.5%\n\nExclusion Criteria -\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>1.5 times the upper limit of normal (ULN)\n* Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection\n* Has an estimated glomerular filtration (eGFR) of \\\u003C60 mL\u002Fmin\u002F1.73m\\^2 at screening\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years","65 Years",{"count":68,"type":69},88,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1","This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.",[75],"Obesity",[77],"siRNA, RNAi therapeutic","2026-06-25",{"date":80,"type":81},"2026-06-29","ACTUAL",{"date":83,"type":81},"2026-06-04",{"date":85,"type":69},"2027-12-14",{"name":5,"class":6},1]